Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure

Eur J Heart Fail. 2004 Jun;6(4):463-6. doi: 10.1016/j.ejheart.2003.12.007.

Abstract

Objective: To assess the effects of carvedilol treatment on the renin-angiotensin system in patients with chronic heart failure (CHF).

Background: Carvedilol improves survival of patients suffering from CHF but the effects of the drug on angiotensin-converting enzyme (ACE) activity, renin and aldosterone are not well characterized in patients receiving an ACE inhibitor.

Methods: A randomized, multicenter, double-blind, 6-month, placebo-controlled study of carvedilol vs. placebo was conducted in 64 CHF patients. Circulating levels of ACE activity, active renin and aldosterone as well as left ventricular diameters and ejection fraction by echography were assessed.

Results: During the study, left ventricular ejection fraction increased from 25+/-11% to 31+/-12% with carvedilol and from 27+/-12% to 28+/-12% with placebo (P=0.03). This beneficial effect was associated with marked blunting of active renin secretion (-53% in the carvedilol group vs.-13% in the placebo group, P=0.04). ACE activity was reduced by 30% in the carvedilol group (P=0.07 vs. placebo). Aldosterone was not changed.

Conclusion: Carvedilol markedly reduced the increase in active renin observed with time despite ACE-inhibitors and tended to decrease ACE activity. These findings may in part explain the beneficial actions of carvedilol and highlights the profound effect of betablockade on renin in patients already receiving ACE-inibitors.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Aged
  • Biomarkers / blood
  • Carbazoles / therapeutic use*
  • Carvedilol
  • Chronic Disease
  • Diastole / drug effects
  • Double-Blind Method
  • Female
  • Heart Failure / drug therapy*
  • Heart Failure / metabolism*
  • Heart Failure / physiopathology
  • Heart Ventricles / drug effects
  • Heart Ventricles / physiopathology
  • Humans
  • Male
  • Middle Aged
  • Peptidyl-Dipeptidase A / drug effects*
  • Peptidyl-Dipeptidase A / metabolism*
  • Propanolamines / therapeutic use*
  • Renin / drug effects*
  • Renin / metabolism*
  • Stroke Volume / drug effects
  • Systole / drug effects
  • Treatment Outcome
  • Ventricular Function, Left / drug effects

Substances

  • Adrenergic beta-Antagonists
  • Biomarkers
  • Carbazoles
  • Propanolamines
  • Carvedilol
  • Peptidyl-Dipeptidase A
  • Renin